Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential

UMMS Affiliation

Department of Biochemistry and Molecular Pharmacology



Document Type


Medical Subject Headings

Animals; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Catalysis; Drug Design; *Drug Discovery; Enzyme Inhibitors; Humans; Hydrolases; Immunologic Factors; Isoenzymes; Models, Molecular; Molecular Structure; Multiple Sclerosis; Neoplasms; Protein Conformation; Structure-Activity Relationship


Biochemistry | Enzymes and Coenzymes | Medicinal-Pharmaceutical Chemistry | Therapeutics


The protein arginine deiminases (PADs), and in particular PAD4, have emerged as potential therapeutic targets for the treatment of rheumatoid arthritis (RA). In this review, evidence linking dysregulated PAD activity to the onset and progression of RA is presented, and the potential role of such aberrant activity in other human diseases, such as multiple sclerosis and cancer, is discussed. The known physiological roles of the PADs, particularly PAD4, and current knowledge regarding PAD structure, catalysis and inhibition are also described.

Rights and Permissions

Citation: Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27.


At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.

Related Resources

Link to Article in PubMed


Protein Arginine Deiminase, Rheumatoid Arthritis, Multiple Sclerosis, Cancer, Treatment, Inhibitors